Yonathan Zehavi

Yonathan Zehavi

Auto-generated profile, based on publicly available information

Yonathan Zehavi

Clinical Laboratory Division, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2026 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Open access
PDF file
MRMoran Landau Rabbi
Moran Landau Rabbi
HMHamutal Meiri
Hamutal Meiri
RMRon Maymon
Ron Maymon
CWChen Weiner
Chen Weiner
YZYonathan Zehavi
Yonathan Zehavi
HCHoward Cuckle
Howard Cuckle
Purpose: Develop a preliminary theoretical model of placental growth factor (PlGF), cell-free DNA fetal fraction (FF) and prior risks in pre-term preeclampsia (PE) and unaffected pregnancies. Methods: Fitting a bivariate Gaussian marker distribution and maternal prior risk factors to a preliminary series. Marker levels were expressed in multiples of the median (MoMs) using fitted regression equations. Unaffected parameters were obtained from the preliminary series; PE parameters from the literature or making reasonable assumptions. Results: 2149 women were tested at 9–14 weeks; pregnancy outcome was not available. Log-linear MoMing equations, after log (PlGF) or square-root (FF) transformation, fitted the data well. Medians in 42 twins were higher than in singletons: PlGF 1.15 and 1.00 MoM, respectively ( P < 0.01); FF 1.35 and 1.01 MoM ( P < 0.0001). There was strong correlation between log PlGF and √FF: in singletons ( R = 0.257, P < 0.0001) and twins ( R = 0.221, although not significant P = 0.16). Applying the model retrospectively, 1 in 60 pre-term PE risk cut-off for singletons and 1 in 12 for twins classified 10.0% as screen-positive. Conclusion: This preliminary theoretical model highlights the parameters requiring modification in a much larger series, and with pregnancy outcome data, before prospective evaluation of combined PlGF and FF screening for PE.